United Therapeutics
Focus: United Therapeutics is a specialty biotech company focused on small molecules and biologics for rare and serious diseases across cardiovascular, oncology, respiratory, nephrology, and infectious disease indications. The company derives 97% of revenue from TYVASO DPI, a peak-stage pulmonary hypertension therapy.
Profile data last refreshed 19h ago · AI intelligence enriched 6d ago
Open Jobs
0
About United Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow United Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from United Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
50 total
LOE Risk
3 in 5yr
ORENITRAM
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$437M Part DStable
Peak15.2yr
Flagship revenue driver comprising 97% of company revenue; mechanism targets vasodilation, platelet inhibition, and smooth muscle proliferation suppression.
Help build intelligence for United Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.